CN106983713A - A kind of stem cell skin care composition and preparation method thereof and application method - Google Patents
A kind of stem cell skin care composition and preparation method thereof and application method Download PDFInfo
- Publication number
- CN106983713A CN106983713A CN201710209077.3A CN201710209077A CN106983713A CN 106983713 A CN106983713 A CN 106983713A CN 201710209077 A CN201710209077 A CN 201710209077A CN 106983713 A CN106983713 A CN 106983713A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- permeable membrane
- skin care
- care composition
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 129
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 59
- 239000012528 membrane Substances 0.000 claims abstract description 57
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229920002079 Ellagic acid Polymers 0.000 claims abstract description 11
- 235000004132 ellagic acid Nutrition 0.000 claims abstract description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 10
- 229930195725 Mannitol Natural products 0.000 claims abstract description 10
- 239000000594 mannitol Substances 0.000 claims abstract description 10
- 235000010355 mannitol Nutrition 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000011187 glycerol Nutrition 0.000 claims abstract description 8
- 239000001509 sodium citrate Substances 0.000 claims abstract description 8
- 235000011083 sodium citrates Nutrition 0.000 claims abstract description 8
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims abstract description 7
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims abstract description 7
- 229960002852 ellagic acid Drugs 0.000 claims abstract description 7
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000006166 lysate Substances 0.000 claims abstract description 5
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960005150 glycerol Drugs 0.000 claims abstract description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 4
- 229960001790 sodium citrate Drugs 0.000 claims abstract description 4
- 229940046009 vitamin E Drugs 0.000 claims abstract description 4
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 4
- 239000011709 vitamin E Substances 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 34
- 239000000843 powder Substances 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 23
- 241000701161 unidentified adenovirus Species 0.000 claims description 19
- 230000001404 mediated effect Effects 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 239000013612 plasmid Substances 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 9
- 230000004927 fusion Effects 0.000 claims description 9
- 241000713666 Lentivirus Species 0.000 claims description 8
- 230000005611 electricity Effects 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 4
- XUNKPNYCNUKOAU-VXJRNSOOSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]a Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUNKPNYCNUKOAU-VXJRNSOOSA-N 0.000 claims description 3
- 101000982010 Homo sapiens Myelin proteolipid protein Proteins 0.000 claims description 3
- 101001126414 Homo sapiens Proteolipid protein 2 Proteins 0.000 claims description 3
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 claims description 3
- 241000219991 Lythraceae Species 0.000 claims description 3
- 101001129124 Mannheimia haemolytica Outer membrane lipoprotein 1 Proteins 0.000 claims description 3
- 101001129122 Mannheimia haemolytica Outer membrane lipoprotein 2 Proteins 0.000 claims description 3
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims description 3
- 241000737052 Naso hexacanthus Species 0.000 claims description 3
- 101000761187 Odontomachus monticola U-poneritoxin(01)-Om1a Proteins 0.000 claims description 3
- 101000642171 Odontomachus monticola U-poneritoxin(01)-Om2a Proteins 0.000 claims description 3
- 108010088535 Pep-1 peptide Proteins 0.000 claims description 3
- 101710149951 Protein Tat Proteins 0.000 claims description 3
- 102100030486 Proteolipid protein 2 Human genes 0.000 claims description 3
- 235000014360 Punica granatum Nutrition 0.000 claims description 3
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 claims description 3
- 102000022540 human calcitonin (9-32) Human genes 0.000 claims description 3
- 108091012306 human calcitonin (9-32) Proteins 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000001178 neural stem cell Anatomy 0.000 claims description 3
- 230000006798 recombination Effects 0.000 claims description 3
- 238000005215 recombination Methods 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 claims description 3
- 108010062760 transportan Proteins 0.000 claims description 3
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims description 2
- 210000003954 umbilical cord Anatomy 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 abstract description 8
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 230000009759 skin aging Effects 0.000 abstract description 4
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 3
- 206010000496 acne Diseases 0.000 abstract description 3
- 230000000774 hypoallergenic effect Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000002087 whitening effect Effects 0.000 abstract description 3
- 238000004108 freeze drying Methods 0.000 abstract 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 9
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 8
- 108010025020 Nerve Growth Factor Proteins 0.000 description 8
- 102000015336 Nerve Growth Factor Human genes 0.000 description 8
- 229940053128 nerve growth factor Drugs 0.000 description 8
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 7
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 7
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 6
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 6
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 6
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 229920000832 Cutin Polymers 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 108700004027 tat Genes Proteins 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical class CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a kind of stem cell skin care composition, it is made up of component A and B component, the mass parts of component A 1 800, obtained including stem cell extract, seralbumin, mannitol, the freeze-drying of Arg9 permeable membranes peptide, wherein, stem cell extract is the stem cell media and the freeze-thaw lysate of the stem cell of culture after culture stem cell；B component according to the mass fraction, including：Glycerine, sodium citrate, ellagic acid, vitamin E, water, in use, component A and B component are mixed.The invention also discloses its preparation method and application method.The present invention all multiple-factors synergy, and can effectively realize these factors passing through skin, strengthens the metabolism of skin from deep layer, delay skin aging, reach whitening, prevention or improve skin wrinkle and wrinkle, go acne, hypo-allergenic purpose.
Description
Technical field
The present invention relates to technical field of skin care, and in particular to a kind of stem cell skin care composition and preparation method thereof and makes
Use method.
Background technology
With the continuous improvement of living standard, maintenance of the people to healthy especially skin is increasingly paid attention to.Skin histology
It is human body maximum tissue organ, is covered in human body surface, the infringement that all harmful substances of barrier nature are produced to viable organism
Effect.But, with the increase at age, the function gradually aging of skin histology organ from the point of view of Aesthetic View, has a strong impact on people
To the enthusiasm of life；From the point of view of physiology, effective protection of human internal organs is influenceed.Then various beauty are protected
Skin product arise at the historic moment.
Stem cell is the cell with propagation and differentiation potential, and the ability replicated with self-renewing can produce height
The functioning cell of differentiation.In addition to height differentiation potential, stem cell can also secrete cytokine profiles, including epidermal growth factor
Sub (EGF), platelet derived growth factor (PDGF), TGF (TGF), basic fibroblast growth factor (b-
FGF), IGF (IGF) and nerve growth factor (NGF) etc..These cell factors can promote application on human skin
Metabolism, promote skin regeneration technique, delay skin aging, make skin recover again elasticity and gloss.But it is presently relevant
Cosmetics and skincare product, be that one or two kinds of cell factors are added in cosmetics and skincare product mostly.The cell factor reparation of skin is one
The complicated regulation process of individual system, one or two kinds of cell factors can not meet the demand of skin repair, cell turnover, a variety of
Agents application could promote epidermal renewal.And these factors are not because modifying, it is impossible to pass through skin, actually can not
Really play a role.
The content of the invention
It is existing to solve it is an object of the invention to provide a kind of stem cell skin care composition and preparation method thereof and application method
There is the deficiency of technology.
The present invention uses following technical scheme：
A kind of stem cell skin care composition, is made up of component A and B component,
Component A 1-800 mass parts, including the freezing of stem cell extract, seralbumin, mannitol, Arg9 permeable membranes peptide are dry
It is dry to obtain, wherein, stem cell extract is the stem cell media and the freezing-thawing and cracking of the stem cell of culture after culture stem cell
Thing；
B component according to the mass fraction, including：
In use, component A and B component are mixed.
Further, seralbumin is the 1% of stem cell extract gross mass, and mannitol is the total matter of stem cell extract
5%, the Arg9 permeable membranes peptide of amount is the 0.05% of stem cell extract gross mass.
Further, prepared by stem cell extract includes the expression of stem cell origin, the stem cell factor that the electric referral of plasmid is led
Expression, the stem cell factor expression of lentivirus mediated or adenovirus mediated stem cell factor expression, wherein, plasmid electricity referral
Stem cell factor expression, the stem cell factor expression of lentivirus mediated or the adenovirus mediated stem cell factor expression system led
When standby, stem cell factor and permeable membrane peptide gene series are constructed and carry out subsequent step after new fusion again, cell because
Son can be inquired about with permeable membrane peptide gene series by amino acid series in password sublist.
Further, stem cell includes umbilical cord mesenchymal stem cells, mesenchymal stem cells MSCs, the fat in animal sources or people source
Fat stem cell, candidate stem cell, NSC or liver stem cells.
Further, permeable membrane peptide species includes with amino acid series：
Permeable membrane peptide Class1：Tat：RKKRRQRRR；
Permeable membrane peptide type 2：VP-22：DAATARGRGRSAASRPTERPRAPARSASRPRRPVD；
Permeable membrane peptide type 3：NTP：RQIKIWFQNRRMKWKK；
Permeable membrane peptide type 4：Transportan：GWT LNSAGYLLGKINLKALAALAKKIL；
Permeable membrane peptide type 5：PEP-1：KETWWETWWTEWSQPKKKRKV；
Permeable membrane peptide type 6：MPG：GALFLGFLGAAGSTMGAWS QPKKKRKV；
Permeable membrane peptide type 7：MAP：KLALKLALKALKAALKLA：
Permeable membrane peptide type 8：KALA：WEAKLAKALAKALAKHLAKALAKALKACEA；
Permeable membrane peptide type 9：ppTG20：GLFRALLRLLRS LWRLLLRA；
Permeable membrane peptide type 10：Arg9：RRRRRRRRR；Or
Permeable membrane peptide type 11：hCT(9-32)：LGTYTQDFNKFHTFPQTAIGVGAP.
Further, the stem cell factor expression used carrier that the electric referral of plasmid is led includes EGFP-N1, N-P3xflag-
CMV or pcDNA3.1；The stem cell factor expression used carrier of lentivirus mediated includes pHBLV-CMVIE-Puro, PLVX-
TRE3G, slow virus packaging system PLVX-Ac-puro, psPAX2, pMD2.G, pPACK-H1-Gag, pPACK-H1-Rev,
pPACK-H1-Vsvg、PLP1、PLP2、PLP-VSVG、pMDLg/pRRE、pRes-Rev、pCMV-VSVG、pCMV-delta R8
Or pCMV-VSVG；Adenovirus mediated stem cell factor expression used carrier include pDC315, pDC316, pDC311,
PDC312, AdMax TM adenovirus systems or AdMaxTM Hi-IQ adenovirus systems.
Further, seralbumin includes people source seralbumin, and animal sources seralbumin, recombination human source serum is white
Albumen, or recombinant animal source seralbumin.
Further, ellagic acid source includes red pomegranate.
The preparation method of above-mentioned stem cell skin care composition, comprises the following steps：
Step 1, the stem cell media by after culture stem cell, the white egg of freeze-thaw lysate, serum of the stem cell of culture
In vain, mannitol, Arg9 permeable membrane peptides mixed freezing are dried, and obtain freeze-dried powder；
Step 2, glycerine, sodium citrate, ellagic acid, vitamin E, water is well mixed, obtains solvent liquid；
The solvent liquid that step 3, freeze-dried powder and step 2 prepared by step 1 are obtained is packed respectively, is remixed when using.
The application method of above-mentioned stem cell skin care composition, comprises the following steps：Freeze-dried powder and solvent liquid are well mixed,
Light shake all is dissolved to freeze-dried powder, is used afterwards；Once in the morning and once at night.
Beneficial effects of the present invention：
1st, research of the present invention based on skin metabolism and the analysis to skin senescence, select suitable component, consumption, many
The factor acts synergistically, restructuring deep skin elastic construction and function, the collagen news speed hydrolysis for make aging deformation, being hardened, and rebuilds glue
Yuanping City weighs, and promotes the rapid aufhellung of skin wrinkle, makes skin show healthy color white touched with red fully.
2nd, the present invention merges the gene of cell factor with permeable membrane peptide gene series, and expression carries the new of permeable membrane peptide and melted
Hop protein, while coordinating artificial synthesized ARG9 permeable membrane peptides, can effectively be realized these factors passing through skin, and skin is strengthened from deep layer
The metabolism of skin, delay skin aging, reach whitening, prevention or improve skin wrinkle and wrinkle, go acne, hypo-allergenic purpose.
3rd, inventive compound (stem cell extract and seralbumin) is preserved with lyophilised state, when using and solvent
Liquid coordinates.As the cell factor of albumen, under lyophilised state, activity-maintaining time's length is mixed when using with solvent liquid, by it
Dissolving, promotes to absorb.
4th, stem cell skin care composition of the present invention is not in without any chemical noxious material, heavy metal and hormone
Secondary damage (chemical noxious material, the heavy metal and hormone is chronic oozes caused by infiltration of skin care item itself functional component to skin
Entering skin causes to use thinning of skin after certain time, long spot, wrinkle increase etc.).It is of the invention main by strengthening skin itself
Metabolic capability, delay skin aging, reach whitening, prevention or improve skin wrinkle, wrinkle, go acne, hypo-allergenic purpose, make for a long time
With without any side effects.It is adapted to the male and female skin care of all age brackets.
Embodiment
The present invention is done with reference to embodiment and further explained.The following example is merely to illustrate the present invention, but
It is not used to limit the practical range of the present invention.
A kind of stem cell skin care composition, is made up of component A and B component,
Component A 1-800 mass parts, including the freezing of stem cell extract, seralbumin, mannitol, Arg9 permeable membranes peptide are dry
It is dry to obtain, wherein, stem cell extract is the stem cell media and the freezing-thawing and cracking of the stem cell of culture after culture stem cell
Thing；Seralbumin is the 1% of stem cell extract gross mass, and mannitol is saturating for 5%, Arg9 of stem cell extract gross mass
Film peptide is the 0.05% of stem cell extract gross mass；
B component according to the mass fraction, including：
In use, component A and B component are mixed.
Prepared by stem cell extract include the expression of stem cell origin, the stem cell factor expression that the electric referral of plasmid is led, slow disease
The stem cell factor expression of poison mediation or adenovirus mediated stem cell factor expression etc., wherein, it is dry that plasmid electricity referral is led
When prepared by cytokine-expressing, the stem cell factor expression of lentivirus mediated or adenovirus mediated stem cell factor expression,
Stem cell factor and permeable membrane peptide gene series are constructed and carry out subsequent step after new fusion again, cell factor with thoroughly
Film peptide gene series can be inquired about by amino acid series in password sublist.Stem cell includes animal sources or the mesenchyma in people source is done
Cell, fat stem cell, NSC or liver stem cells etc..Permeable membrane peptide species includes but is not limited to the sour series of propylhomoserin：
Permeable membrane peptide Class1：Tat：RKKRRQRRR；
Permeable membrane peptide type 2：VP-22：DAATARGRGRSAASRPTERPRAPARSASRPRRPVD；
Permeable membrane peptide type 3：NTP：RQIKIWFQNRRMKWKK；
Permeable membrane peptide type 4：Transportan：GWT LNSAGYLLGKINLKALAALAKKIL；
Permeable membrane peptide type 5：PEP-1：KETWWETWWTEWSQPKKKRKV；
Permeable membrane peptide type 6：MPG：GALFLGFLGAAGSTMGAWS QPKKKRKV；
Permeable membrane peptide type 7：MAP：KLALKLALKALKAALKLA：
Permeable membrane peptide type 8：KALA：WEAKLAKALAKALAKHLAKALAKALKACEA；
Permeable membrane peptide type 9：ppTG20：GLFRALLRLLRS LWRLLLRA；
Permeable membrane peptide type 10：Arg9：RRRRRRRRR；Or
Permeable membrane peptide type 11：hCT(9-32)：LGTYTQDFNKFHTFPQTAIGVGAP.
Seralbumin includes people source seralbumin, animal sources seralbumin, recombination human source seralbumin, or again
Group animal sources seralbumin.Ellagic acid source includes red pomegranate etc..
The preparation method of above-mentioned stem cell skin care composition, comprises the following steps：
Step 1, the stem cell media by after culture stem cell, the white egg of freeze-thaw lysate, serum of the stem cell of culture
In vain, mannitol, Arg9 permeable membrane peptides mixed freezing are dried, and obtain freeze-dried powder；
Step 2, glycerine, sodium citrate, ellagic acid, vitamin E, water is well mixed, obtains solvent liquid；
The solvent liquid that step 3, freeze-dried powder and step 2 prepared by step 1 are obtained is packed respectively, is remixed when using.
The application method of the stem cell skin care composition of above-mentioned preparation, comprises the following steps：Freeze-dried powder and solvent liquid are mixed
Close uniform, light shake all is dissolved to freeze-dried powder, is used afterwards；Once in the morning and once at night.Clear water or mildy wash cleaning skin are first used,
Take appropriate product gently to smear in skin surface, pat until all absorptions.Morning is late using other cosmetics are reused after half an hour
Suggestion does not use other skin care item after upper use.
Embodiment 1 is using the expression of stem cell origin
1st, the preparation of freeze-dried powder：
1.1 stem cells are cultivated：The stem cell 10000000 recovered is inoculated in T75 with 15 milliliters of stem cell medias
Tissue Culture Flask, in 5%CO2With 37 DEG C under the conditions of cultivate 48-72 hours.Wherein, stem cell media formula is such as the institute of table 1
Show.
Table 1
| Reagent | Stock solution concentration | Article No. | Final concentration | Amount needed for 100mL culture mediums |
| KnockOutTM DMEM CTSTM | — | A12861 | 1X | 82.75mL |
| KnockOutTM SR XenoFree CTSTM | — | 12618 | 15% | 15mL |
| GlutaMAXTM-I CTSTM | 200mM | A12860 | 2mM | 1mL |
| NEAA | 10mM | 11140 | 0.1mM | 1mL |
| bFGF | 10μg/mL | 13256 | 8ng/mL | 80μL |
| 2-Mercaptoethanol | 55mM | 21985 | 0.1mM | 182μL |
1.2 collect and handle：The stem cell media after culture stem cell is collected, is separately stored in standby in sterile chamber；With
Sterile saline washes the stem cell of culture twice, plus 1 milliliter of trypsase, and 37 degree are handled 5 minutes, suctions out the dry thin of digestion
Born of the same parents, are collected into 2 milliliters of EP pipes, and 56 degree are handled 10 minutes, then are frozen in -80 degree refrigerator 30 minutes, then are placed in 56 degree of water-baths
Until dissolving, (freeze, dissolve) so repeatedly for three times.12000 revs/min centrifuge 10 minutes, collect supernatant and with above-mentioned nothing
Stem cell media mixing in bacterium container, more than ten times of concentration in 10K molecular sieve, the mannitol of addition 5%, 1%
Seralbumin, 0.05% Arg9 permeable membrane peptides, are well mixed, then are placed in -80 degree refrigerator overnights, are freezed in freeze drier
Dry, obtain freeze-dried powder.
2nd, by 4 × 106Ug glycerine, 2 × 106Ug sodium citrates, 15ug ellagic acids, 10ug vitamin Es, 15 × 106Ug water is mixed
Close uniform, obtain solvent liquid.
3rd, freeze-dried powder prepared by step 1 takes 400ug individually to pack, and solvent liquid prepared by step 2 is individually packed.
4th, in use, freeze-dried powder and solvent liquid are mixed.
The stem cell factor expression that embodiment 2 is led using the electric referral of plasmid
1st, the preparation of freeze-dried powder：
1.1 respectively by EGF (EGF), platelet derived growth factor (PDGF), TGF (TGF),
Basic fibroblast growth factor (b-FGF), IGF (IGF) and nerve growth factor (NGF), people's cutin
Porcine HGF (KGF-2), interleukin-1 receptor antagonist (IL-1R) gene 5 ' end are serial with permeable membrane peptide TAT genes respectively
Fusion, and the gene after fusion is cloned into EGFP-N1 carriers respectively.The carrier expressed for stem cell factor is not limited to
EGFP-N1 carriers, including the other carrier that can be expressed in zooblast such as N-P3xflag-CMV, pcDNA3.1 etc..
1.2nd, stem cell electricity conversion
1.2.1 the preparation of stem cell before converting：(1) attached cell stem cell is transferred to 75cm2Tissue Culture Flask culture, extremely
Make cell confluency degree about 50-70% before conversion.Now cell number is about 2-10x106, and electricity turns to need about 1-10x10 every time5It is individual thin
Born of the same parents.(2) 12ml PBS slowly rinse cell.(3) PBS is suctioned out, 0.4ml trypsin digestion and cells are used.(4) add 10ml and contain blood
Clear culture medium, neutralizes pancreatin.(5) 400x centrifuges 5-7min and collects cell.(6) with the weight such as PBS, Hepes, serum free medium
Outstanding cell, is allowed to density for 1-5x106cell/ml。
1.2.2 electricity conversion：(1) electric carryover sequence, or selection pre-set programs are set.(2) above-mentioned plasmid is added into electric revolving cup, institute
Depending on plasmid amount is needed according to cell difference, general initial concentration is 10-50ug/ml.(3) cell is added into electric shock cup, top turns
Electric shock cup is allowed to mix.The use suggestion of cell concentration and volume refer to table 2.
Table 2
(4) electric shock cup is put into electric shock tank, pulse electric shock is once.(5) after pulse, cell is transferred to and contains 0.5ml
(6) gently rock orifice plate in the hole of stem cell media, are uniformly distributed cell, incubator culture.(7) electricity turns 24-48 hours
Afterwards, collect and handle with reference to embodiment 1, obtain freeze-dried powder.
2nd, by 2.5 × 106Ug glycerine, 0.1 × 106Ug sodium citrates, 0.1ug ellagic acids, 0.1ug vitamin Es, 10 ×
106Ug water is well mixed, and obtains solvent liquid.
3rd, freeze-dried powder prepared by step 1 takes 1ug individually to pack, and solvent liquid prepared by step 2 is individually packed.
4th, in use, freeze-dried powder and solvent liquid are mixed.
Embodiment 3 is expressed using the stem cell factor of lentivirus mediated
1st, the preparation of freeze-dried powder：
1.1 respectively by EGF (EGF), platelet derived growth factor (PDGF), TGF (TGF),
Basic fibroblast growth factor (b-FGF), IGF (IGF) and nerve growth factor (NGF), people's cutin
Porcine HGF (KGF-2), interleukin-1 receptor antagonist (IL-1R) gene 5 ' end are serial with permeable membrane peptide TAT genes respectively
Fusion, and the gene after fusion is cloned into pHBLV-CMVIE-Puro carriers respectively.Eight expression vector plasmids are obtained altogether, point
PHBLV-CMVIE-EGF, pHBLV-CMVIE-PDGF, pHBLV-CMVIE-TGF, pHBLV-CMVIE-b-FGF are not named as,
PHBLV-CMVIE-IGF, pHBLV-CMVIE-NGF, pHBLV-CMVIE-KGF-2, pHBLV-CMVIE-IL-1R.Slow virus table
PHBLV-CMVIE-Puro, in addition to other Lentivirals such as PLVX-TRE3G, slow virus packaging are not limited to up to carrier
System PLVX-Ac-puro, psPAX2, pMD2.G, pPACK-H1-Gag, pPACK-H1-Rev, pPACK-H1-Vsvg, PLP1,
PLP2, PLP-VSVG, pMDLg/pRRE, pRes-Rev, pCMV-VSVG, pCMV-delta R8, pCMV-VSVG etc..
1.2 slow virus are packed：Each support samples need 1 × 106In individual 293T cells, this method because have 8 it is different
Expression vector plasmid, need to pack 8 different slow virus, comprise the following steps that altogether：(1) 1.5ml sterilizing EP pipes, are taken, 1.5 are added
(pHBLV-CMVIE-X, X represent different eight above for μ g packaging mixing plasmids (pMD2.G and pspAX2) and 0.5 μ g expression plasmids
Gene) and 250 μ l serum-free Opti MEM.It is soft to mix, it is incubated at room temperature 5min.(2) 1.5ml sterilizing EP pipes, are taken, 9 μ are taken
L liposomes 2000l is dissolved in 250 μ l serum-free Opti-MEM I culture mediums.It is soft to mix, it is incubated at room temperature 5min.(3), by DNA
Solution and liposome solutions are softly mixed.It is incubated at room temperature 20min.(4), digested with pancreatin and the 293FT cells that count.With containing serum
DMEM culture mediums be resuspended cell.(5), per hole in six orifice plates, growth mediums of the 1ml containing serum is added, DNA- is added
Liposome complex.(6), the 293FT cells (1 × 10 that 1ml is resuspended6Individual cell/ml) it is added in flat board.37℃CO2Incubator
It is middle to be incubated overnight.(7) culture medium containing DNA- liposome complexes, is removed, instead DMEM (contains Sodium Pyruvate and nonessential
Amino acid).(8) supernatant of the 48-72h harvests containing virus after, transfecting.3000rpm centrifuges 20min, removes precipitation, and supernatant is used
0.45um filtering with microporous membrane.(9), -80 DEG C of storages of viral supernatants, to preserve 1 year.The slow virus of packaging out is to NIH/
3T3 cells are up to more than 90% efficiency of infection.
The infection and culture of 1.3 stem cells：Attached cell stem cell is transferred to eight bottles of 75cm2Tissue Culture Flask culture, extremely
Make cell confluency degree about 50-70% before conversion.Now cell number is about 2-10x106.By be collected into 3.2 eight kinds of slow virus
Stem cell is infected respectively, adds 1ml slow virus culture medium and the virus liquid of 1ml room-temperature dissolutions, final concentration of 4ug/ml
Cell is positioned in fresh stem cell media and cultivated 48 hours by polybere, second day subinfection again.
1.4 collect and handle with reference to embodiment 1, obtain freeze-dried powder.
2nd, by 6.5 × 106Ug glycerine, 3 × 106Ug sodium citrates, 30ug ellagic acids, 20ug vitamin Es, 20 × 106Ug water
It is well mixed, obtain solvent liquid.
3rd, freeze-dried powder prepared by step 1 takes 800ug individually to pack, and solvent liquid prepared by step 2 is individually packed.
4th, in use, freeze-dried powder and solvent liquid are mixed.
Embodiment 4 is expressed using adenovirus mediated stem cell factor
1st, the preparation of freeze-dried powder：
1.1st, respectively by EGF (EGF), platelet derived growth factor (PDGF), TGF (TGF),
Basic fibroblast growth factor (b-FGF), IGF (IGF) and nerve growth factor (NGF), people's cutin
Porcine HGF (KGF-2), interleukin-1 receptor antagonist (IL-1R) gene 5 ' end respectively with permeable membrane peptide TAT gene lines
Row fusion, and the gene after fusion is cloned into adenovirus vector pDC315 respectively and pDC315-EGF, pDC315- is named as
PDGF、pDC315-TGF、pDC315-b-FGF、pDC315-IGF、pDC315-NGF、pDC315-KGF-2、pDC315-IL-1R。
Adenovirus expression carrier include pDC315, pDC316, pDC311, pDC312, and AdMax TM adenovirus systems with
AdMaxTM Hi-IQ adenovirus systems etc..
1.2nd, respectively by pDC315-EGF, pDC315-PDGF, pDC315-TGF, pDC315-b-FGF, pDC315-IGF,
PDC315-NGF, pDC315-KGF-2, pDC315-IL-1R and carrier pBGHloxp △ E3 pass through L ipo2fectamine2000
Cotransfection is to 293 cells.There is virus plaque within 9~14 days after cotransfection, purified by 3 virus plaques, using Q IAamp
DNA BloodMini Kit extract recombinant dna, identified correct propagating defects type adenovirus be named as pDC-EGF,
PDC-PDGF, pDC-TGF, pDC-b-FGF, pDC-IGF, pDC-NGF, pDC-KGF-2, pDC-IL-1R, carry out a large amount of amplifications and
Purifying, and carry out titer determination.
1.3rd, infection of the adenovirus to stem cell
Attached cell stem cell is transferred to eight bottles of 75cm2Tissue Culture Flask culture, makes cell confluency degree about 50- to before converting
70%.Now cell number is about 2-10x106.Each bottle infect respectively pDC-EGF, pDC-PDGF, pDC-TGF, pDC-b-FGF,
pDC-IGF、pDC-NGF、pDC-KGF-2、pDC-IL-1R.Add after stem cell media and cultivate 72 hours.
1.4th, collect and handle with reference to embodiment 1, obtain freeze-dried powder.
2nd, by 2.5 × 106Ug glycerine, 3 × 106Ug sodium citrates, 10ug ellagic acids, 10ug vitamin Es, 10 × 106Ug water
It is well mixed, obtain solvent liquid.
3rd, freeze-dried powder prepared by step 1 takes 300ug individually to pack, and solvent liquid prepared by step 2 is individually packed.
4th, in use, freeze-dried powder and solvent liquid are mixed.
Claims (10)
1. a kind of stem cell skin care composition, it is characterised in that be made up of component A and B component,
Component A 1-800 mass parts, including stem cell extract, seralbumin, mannitol, Arg9 permeable membrane peptides are freeze-dried
Arrive, wherein, stem cell extract is the stem cell media and the freeze-thaw lysate of the stem cell of culture after culture stem cell；
B component according to the mass fraction, including：
In use, component A and B component are mixed.
2. stem cell skin care composition according to claim 1, it is characterised in that seralbumin is stem cell extract
The 1% of gross mass, mannitol is that 5%, the Arg9 permeable membranes peptide of stem cell extract gross mass is stem cell extract gross mass
0.05%.
3. stem cell skin care composition according to claim 1, it is characterised in that prepared by stem cell extract include doing thin
The expression of born of the same parents' origin, the stem cell factor expression that the electric referral of plasmid is led, the stem cell factor expression of lentivirus mediated or adenovirus
The stem cell factor expression of mediation, wherein, the stem cell factor that plasmid electricity referral is led is expressed, the stem cell factor of lentivirus mediated
When prepared by expression or the expression of adenovirus mediated stem cell factor, stem cell factor is constructed with permeable membrane peptide gene series
Subsequent step is carried out after new fusion again, cell factor can be by amino acid series in codon with permeable membrane peptide gene series
Inquired about in table.
4. stem cell skin care composition according to claim 3, it is characterised in that stem cell includes animal sources or people source
Umbilical cord mesenchymal stem cells, mesenchymal stem cells MSCs, fat stem cell, candidate stem cell, NSC or liver stem cells.
5. stem cell skin care composition according to claim 3, it is characterised in that permeable membrane peptide species and amino acid series bag
Include：
Permeable membrane peptide Class1：Tat：RKKRRQRRR；
Permeable membrane peptide type 2：VP-22：DAATARGRGRSAASRPTERPRAPARSASRPRRPVD；
Permeable membrane peptide type 3：NTP：RQIKIWFQNRRMKWKK；
Permeable membrane peptide type 4：Transportan：GWT LNSAGYLLGKINLKALAALAKKIL；
Permeable membrane peptide type 5：PEP-1：KETWWETWWTEWSQPKKKRKV；
Permeable membrane peptide type 6：MPG：GALFLGFLGAAGSTMGAWS QPKKKRKV；
Permeable membrane peptide type 7：MAP：KLALKLALKALKAALKLA：
Permeable membrane peptide type 8：KALA：WEAKLAKALAKALAKHLAKALAKALKACEA；
Permeable membrane peptide type 9：ppTG20：GLFRALLRLLRS LWRLLLRA；
Permeable membrane peptide type 10：Arg9：RRRRRRRRR；Or
Permeable membrane peptide type 11：hCT(9-32)：LGTYTQDFNKFHTFPQTAIGVGAP.
6. stem cell skin care composition according to claim 3, it is characterised in that the stem cell factor that plasmid electricity referral is led
Expressing used carrier includes EGFP-N1, N-P3xflag-CMV or pcDNA3.1；The stem cell factor expression institute of lentivirus mediated
With carrier include pHBLV-CMVIE-Puro, PLVX-TRE3G, slow virus packaging system PLVX-Ac-puro, psPAX2,
pMD2.G、pPACK-H1-Gag、pPACK-H1-Rev、pPACK-H1-Vsvg、PLP1、PLP2、PLP-VSVG、pMDLg/pRRE、
PRes-Rev, pCMV-VSVG, pCMV-delta R8 or pCMV-VSVG；Adenovirus mediated stem cell factor expression is used to be carried
Body includes pDC315, pDC316, pDC311, pDC312, AdMax TM adenovirus systems or AdMaxTM Hi-IQ adenovirus
Carrier system.
7. stem cell skin care composition according to claim 1, it is characterised in that it is white that seralbumin includes people source serum
Albumen, animal sources seralbumin, recombination human source seralbumin, or recombinant animal source seralbumin.
8. stem cell skin care composition according to claim 1, it is characterised in that ellagic acid source includes red pomegranate.
9. the preparation method of the stem cell skin care composition described in claim 1-8 any claims, it is characterised in that including
Following steps：
Step 1, the stem cell media after stem cell will be cultivated, it is the freeze-thaw lysate of stem cell of culture, seralbumin, sweet
Reveal alcohol, Arg9 permeable membrane peptides mixed freezing to dry, obtain freeze-dried powder；
Step 2, glycerine, sodium citrate, ellagic acid, vitamin E, water is well mixed, obtains solvent liquid；
The solvent liquid that step 3, freeze-dried powder and step 2 prepared by step 1 are obtained is packed respectively, is remixed when using.
10. the application method of stem cell skin care composition prepared by claim 9, it is characterised in that comprise the following steps：It will freeze
Dry powder and solvent liquid are well mixed, and light shake all is dissolved to freeze-dried powder, is used afterwards；Once in the morning and once at night.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710209077.3A CN106983713B (en) | 2017-03-31 | 2017-03-31 | Stem cell skin care composition and preparation method and using method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710209077.3A CN106983713B (en) | 2017-03-31 | 2017-03-31 | Stem cell skin care composition and preparation method and using method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106983713A true CN106983713A (en) | 2017-07-28 |
| CN106983713B CN106983713B (en) | 2020-06-26 |
Family
ID=59415426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710209077.3A Active CN106983713B (en) | 2017-03-31 | 2017-03-31 | Stem cell skin care composition and preparation method and using method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106983713B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107951820A (en) * | 2017-12-01 | 2018-04-24 | 重庆金时代生物技术有限公司 | A kind of stem cell skin care composition and preparation method thereof |
| CN108771638A (en) * | 2018-07-22 | 2018-11-09 | 张晓南 | A kind of biomass placenta freeze-dried powder preparation and preparation method thereof |
| CN109394563A (en) * | 2018-11-06 | 2019-03-01 | 福建省海西细胞生物工程有限公司 | A kind of preparation method of stem cell media liposome and the application in skin care item |
| CN110878287A (en) * | 2019-12-05 | 2020-03-13 | 伯仕利生物科技发展（盐城）有限公司 | Preparation method and application of stem cell supernatant over-expressing TAT-KGF |
| CN111407717A (en) * | 2020-03-27 | 2020-07-14 | 河北银丰鼎诚生物技术有限公司 | Stem cell factor freeze-dried powder and preparation method and application thereof |
| CN113304063A (en) * | 2021-04-23 | 2021-08-27 | 四川省恩乐生物工程有限公司 | Composition for skin beautifying and anti-aging and preparation method thereof |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1624113A (en) * | 2004-11-17 | 2005-06-08 | 中国医学科学院北京协和医院 | Biological differentiation revellent, its preparation process and application differenting inducing in from stem cells to cardiacy muscular tissue cells |
| CN1687117A (en) * | 2005-04-01 | 2005-10-26 | 陕西九州科技股份有限公司 | Active polypeptide possessing action for promoting mitosis of horny cell and its application |
| CN101711874A (en) * | 2008-10-08 | 2010-05-26 | 广州暨南大学医药生物技术研究开发中心 | Application of cell penetrating peptide Tat-mediated growth factor in transdermal transfer |
| CN103191445A (en) * | 2013-04-19 | 2013-07-10 | 吉林大学 | Use of mesenchymal stem cell and preparation method thereof |
| CN103494723A (en) * | 2013-06-26 | 2014-01-08 | 马玉贤 | Stem cell skin care composition and manufacturing method and application thereof |
| CN103705392A (en) * | 2012-09-29 | 2014-04-09 | 黄兵 | Small nucleic acid whitening and freckle-removing cream, and preparation method thereof |
| CN104073516A (en) * | 2014-05-27 | 2014-10-01 | 浙江大学 | Gene vector as well as preparation method and application thereof |
| CN104694573A (en) * | 2015-03-26 | 2015-06-10 | 中国科学院武汉病毒研究所 | Method for inhibiting HIV-1 infectious agent from infecting primary lymphocyte by utilizing CRISPR/Cas9 |
| CN105078777A (en) * | 2014-05-15 | 2015-11-25 | 金凤华 | Mesenchymal stem cell excreted factor essence, and preparation method and application thereof |
| CN105175526A (en) * | 2015-08-25 | 2015-12-23 | 三峡大学 | Cell-penetrating peptide hPP8 and application thereof |
| CN105504066A (en) * | 2016-01-16 | 2016-04-20 | 广州市科玮生物技术有限公司 | Application of fusion protein in cosmetics |
| CN105543313A (en) * | 2015-12-29 | 2016-05-04 | 四川新生命干细胞科技股份有限公司 | Human-derived mesenchymal stem cell factor, and preparation method and application thereof |
| CN106038464A (en) * | 2016-07-11 | 2016-10-26 | 佛山杰致信息科技有限公司 | Composite anti-wrinkle skin care product and preparation method thereof |
| CN106943338A (en) * | 2017-05-19 | 2017-07-14 | 何向锋 | Personalized beauty care skin care item and preparation method thereof |
| CN107034196A (en) * | 2017-05-19 | 2017-08-11 | 何向锋 | Expression restructuring T α 1 adoptive immunity cell and its production and use |
| CN107951820A (en) * | 2017-12-01 | 2018-04-24 | 重庆金时代生物技术有限公司 | A kind of stem cell skin care composition and preparation method thereof |
| CN108060137A (en) * | 2017-12-26 | 2018-05-22 | 博生吉医药科技(苏州)有限公司 | The NK92 cells of IL7 and IL21 modifications, preparation method and applications |
-
2017
- 2017-03-31 CN CN201710209077.3A patent/CN106983713B/en active Active
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1624113A (en) * | 2004-11-17 | 2005-06-08 | 中国医学科学院北京协和医院 | Biological differentiation revellent, its preparation process and application differenting inducing in from stem cells to cardiacy muscular tissue cells |
| CN1687117A (en) * | 2005-04-01 | 2005-10-26 | 陕西九州科技股份有限公司 | Active polypeptide possessing action for promoting mitosis of horny cell and its application |
| CN101711874A (en) * | 2008-10-08 | 2010-05-26 | 广州暨南大学医药生物技术研究开发中心 | Application of cell penetrating peptide Tat-mediated growth factor in transdermal transfer |
| CN103705392A (en) * | 2012-09-29 | 2014-04-09 | 黄兵 | Small nucleic acid whitening and freckle-removing cream, and preparation method thereof |
| CN103191445A (en) * | 2013-04-19 | 2013-07-10 | 吉林大学 | Use of mesenchymal stem cell and preparation method thereof |
| CN103494723A (en) * | 2013-06-26 | 2014-01-08 | 马玉贤 | Stem cell skin care composition and manufacturing method and application thereof |
| CN105078777A (en) * | 2014-05-15 | 2015-11-25 | 金凤华 | Mesenchymal stem cell excreted factor essence, and preparation method and application thereof |
| CN104073516A (en) * | 2014-05-27 | 2014-10-01 | 浙江大学 | Gene vector as well as preparation method and application thereof |
| CN104694573A (en) * | 2015-03-26 | 2015-06-10 | 中国科学院武汉病毒研究所 | Method for inhibiting HIV-1 infectious agent from infecting primary lymphocyte by utilizing CRISPR/Cas9 |
| CN105175526A (en) * | 2015-08-25 | 2015-12-23 | 三峡大学 | Cell-penetrating peptide hPP8 and application thereof |
| CN105543313A (en) * | 2015-12-29 | 2016-05-04 | 四川新生命干细胞科技股份有限公司 | Human-derived mesenchymal stem cell factor, and preparation method and application thereof |
| CN105504066A (en) * | 2016-01-16 | 2016-04-20 | 广州市科玮生物技术有限公司 | Application of fusion protein in cosmetics |
| CN106038464A (en) * | 2016-07-11 | 2016-10-26 | 佛山杰致信息科技有限公司 | Composite anti-wrinkle skin care product and preparation method thereof |
| CN106943338A (en) * | 2017-05-19 | 2017-07-14 | 何向锋 | Personalized beauty care skin care item and preparation method thereof |
| CN107034196A (en) * | 2017-05-19 | 2017-08-11 | 何向锋 | Expression restructuring T α 1 adoptive immunity cell and its production and use |
| CN107951820A (en) * | 2017-12-01 | 2018-04-24 | 重庆金时代生物技术有限公司 | A kind of stem cell skin care composition and preparation method thereof |
| CN108060137A (en) * | 2017-12-26 | 2018-05-22 | 博生吉医药科技(苏州)有限公司 | The NK92 cells of IL7 and IL21 modifications, preparation method and applications |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107951820A (en) * | 2017-12-01 | 2018-04-24 | 重庆金时代生物技术有限公司 | A kind of stem cell skin care composition and preparation method thereof |
| CN108771638A (en) * | 2018-07-22 | 2018-11-09 | 张晓南 | A kind of biomass placenta freeze-dried powder preparation and preparation method thereof |
| CN109394563A (en) * | 2018-11-06 | 2019-03-01 | 福建省海西细胞生物工程有限公司 | A kind of preparation method of stem cell media liposome and the application in skin care item |
| CN110878287A (en) * | 2019-12-05 | 2020-03-13 | 伯仕利生物科技发展（盐城）有限公司 | Preparation method and application of stem cell supernatant over-expressing TAT-KGF |
| CN111407717A (en) * | 2020-03-27 | 2020-07-14 | 河北银丰鼎诚生物技术有限公司 | Stem cell factor freeze-dried powder and preparation method and application thereof |
| CN113304063A (en) * | 2021-04-23 | 2021-08-27 | 四川省恩乐生物工程有限公司 | Composition for skin beautifying and anti-aging and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106983713B (en) | 2020-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106983713A (en) | A kind of stem cell skin care composition and preparation method thereof and application method | |
| US10980837B2 (en) | Lyophilized platelet lysates | |
| Dan et al. | The influence of cellular source on periodontal regeneration using calcium phosphate coated polycaprolactone scaffold supported cell sheets | |
| Wang et al. | Bone marrow stem cells implantation with α-cyclodextrin/MPEG–PCL–MPEG hydrogel improves cardiac function after myocardial infarction | |
| CN108823156A (en) | For the clinical grade human umbilical cord mesenchymal stem cells composite factor of reparation and the preparation method of freeze-dried powder | |
| CN106109496A (en) | Human umbilical cord mesenchymal stem cells extract freeze-drying powder and preparation method | |
| EP2368974A1 (en) | Methods for isolating mesenchymal stem cells from embryos of human or animals and extracting secretion substances thereof | |
| Huang et al. | Stem/progenitor cell in kidney: characteristics, homing, coordination, and maintenance | |
| KR101542849B1 (en) | Method for Differentiating Pluripotency Stem Cell Induced from Mesenchymal Stem Cell into Hepatocyte | |
| KR101542846B1 (en) | Method for Differentiating Pluripotency Stem Cell Induced from Mesenchymal Stem Cell into Chondrocyte | |
| CN108159078A (en) | A kind of Porcine HGF freeze-dried powder, preparation method and application | |
| KR101542847B1 (en) | Method for Differentiating Pluripotency Stem Cell Induced from Mesenchymal Stem Cell into Neuron | |
| Kim et al. | In situ chondrogenic differentiation of bone marrow stromal cells in bioactive self-assembled peptide gels | |
| CN108478600A (en) | Mescenchymal stem cell excretion body is preparing the application in preventing osteoporosis agents | |
| CN105039247A (en) | Preparation used for inducing stem cells to differentiate towards chondrogenesis and preparation method and application of preparation | |
| CN113144221A (en) | Exosome preparation and preparation method and application thereof | |
| CN112481206A (en) | Culture medium and culture method for inducing secretion of adipose-derived mesenchymal stem cell factor | |
| CN106606512B (en) | Mixed cell preparation for treating myocardial infarction and preparation method and application thereof | |
| KR101542848B1 (en) | Method for Differentiating Pluripotency Stem Cell Induced from Mesenchymal Stem Cell into Osteoblast | |
| KR101542850B1 (en) | Method for Differentiating Pluripotency Stem Cell Induced from Mesenchymal Stem Cell into Adipocyte | |
| CN105708722A (en) | Factor composition and composite freeze-dried powder for promoting skin cell growth and skin care product | |
| CN103446628B (en) | Preparation method for tissue engineering nerves of compound seed cells | |
| RU2662172C2 (en) | Method for producing regenerative veterinary preparation based on extract of mesenchimal stem cells and conditioned medium | |
| CN111961681B (en) | Method for enriching exosomes in extracellular matrix, ECM biomaterial rich in exosomes and application | |
| KR101544195B1 (en) | Method for Preparing Induced Pluripotency Stem Cell from Mesenchymal Stem Cell and Production thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |